4-Hydroxyhexenal (HHE) impairs glutamate transport in astrocyte cultures

Journal of Alzheimer's Disease

Volumn 32, Issue 1, 2012, Pages 139-146

  Lovell, Mark A ^a,b   Bradley, Melissa A ^a   Fister, Shuling X ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

4 hydroxyhexenal; Excitatory amino acid transporter 2; glutamate transport; lipid peroxidation

Indexed keywords

4 HYDROXYHEXENAL; ALDEHYDE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANTIBODY LABELING; ARTICLE; ASTROCYTE; CASE REPORT; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; IMMUNOPRECIPITATION; LATE STAGE ALZHEIMER DISEASE; MALE; MILD COGNITIVE IMPAIRMENT; NERVE CELL CULTURE; NONHUMAN; PARAHIPPOCAMPAL GYRUS; PRECLINICAL ALZHEIMER DISEASE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

EID: 84867558228     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120409     Document Type: Article

References (70)

1. Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35, 7497-7504.
2. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
3. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA (1999) Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893, 362-364.
4. Shan X, Tashiro H, Lin CL (2003) The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 23, 4913-4921.
5. Sultana R, Butterfield DA (2010) Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19, 341-353.
6. McGarth LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q J Med 94, 385-490.
7. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22, 187-194.
8. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 33-36.
9. Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27, 1094-1099.
10. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM,Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: Brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39, 221-228.
11. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer disease: Insights into memory loss in MCI. J Alzheimers Dis 23, 257-269.
12. Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48, 1570-1576.
13. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA (2012) Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging 33, 1034-1044.
14. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD (2005) F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7, 269-275.
15. Catala A (2009) Lipid peroxidation of membrane phopholipids generates hydroxy-alkenals and oxidized phopholipids active in physiological and/or pathological conditions. Chem Physics Lipids 157, 1-11.
16. Van Kuijk FJ, Holte LL, Dratz EA (1990) 4-hydroxhexenal: A lipid peroxidation product derived from oxidized docosahexaenoic acid. Biochim Biophys Acta 1043, 116-118.
17. LoPachin RM, Barber DS, Gavin T (2008) Molecular mechanisms of the conjugated alpha, beta-unsaturated carbonyl derivatives: Relevance to neurotoxicity and neurodegenerative diseases. Toxicol Sci 104, 235-249.
18. LoPachin RM, Gavin T, Petersen DR, Barber DS (2009) Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: Nucleophilic targets and adduct formation. Chem Res Toxicol 22, 1499-1508.
19. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22, 187-194.
20. Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 150, 437-443.
21. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18, 457-461.
22. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA (2012) Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging 33, 1034-1044.
23. Lovell MA, Xie C, Markesbery WR (2000) Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic Biol Med 29, 714-720.
24. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68, 255-264.
25. Keller JN, Germeyer A, Begley JG, Mattson MP (1997) 17Beta-estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid beta-peptide and iron. J Neurosci Res 50, 522-530.
26. Pocernich CB, Butterfield DA (2003) Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease. Neurotox Res 5, 515-520.
27. Mattson MP, Fu W, Waeg G, Uchida K (1997) 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8, 2275-2281.
28. Long EK, Murphy TC, Leiphon LJ,Watt J, MorrowJD, Milne GL, Howard JR, Picklo MJ Sr (2008) Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem 105, 714-724.
29. Long EK, Rosenberger TA, PickloMJSr (2010) Ethanol withdrawal increases glutathione adducts of 4-hydroxy-2-hexenal but not 4-hydroxyl-2-nonenal in the rat cerebral cortex. Free Radic Biol Med 48, 384-390.
30. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
32. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63, 38-46.
33. National Institute on Aging and the Reagan Institute Working on Group Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease (1997). Neurobiol Aging 18, S1-S2.
34. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Ruther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 81, 481-496.
35. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, Waeg G, Mattson MP (1997) 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 80, 685-696.
36. Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 20, 83-90.
37. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63.
38. SwansonRA(1992) Astrocyte glutamate uptake during chemical hypoxia in vitro. Neurosci Lett 147, 143-146.
39. Leonova J, Thorlin T, Aberg ND, Eriksson PS, Ronnback L, Hansson E (2001) Endothelin-1 decreases glutamate uptake in primary cultured rat astrocytes. Am J Physiol 281, C1495-C1503.
40. Lipton SA (2007) Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 8, 803-808.
41. Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S (2008) Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29, 1619-1630.
42. Ferrarese C, Begni B, Canevari C, Zoia C, Piolti R, Frigo M, Appollonio I, Frattola L (2000) Glutamate uptake is decreased in platelets from Alzheimer's disease patients. Ann Neurol 47, 641-643.
43. Ferrarese C, Sala G, Riva R, Begni B, Zoia C, Tremolizzo L, Galimberti G, Millul A, Bastone A, Mennini T, Balzarini C, Frattola L, Beghi E (2001) Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology 56, 270-272.
44. Beart PM, O'Shea RD (2007) Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement. Br J Pharmacol 150, 5-17.
45. Cross AJ, Slater P, Simpson M, Royston C, Deakin JF, Perry RH, Perry EK (1987) Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases. Neurosci Lett 79, 213-217.
46. Hardy J, Cowburn R, Barton A, Reynolds G, Lofdahl E, O'Carroll AM, Wester P, Winblad B (1987) Region-specific loss of glutamate innervation in Alzheimer's disease. Neurosci Lett 73, 77-80.
47. Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R (2002) Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem 80, 807-814.
48. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR (2011) Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging 32, 553.e1-e11.
49. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, Kaye JA, Quinn JF, Silbert L, Erten-Lyons D, Leverenz JB, Bird TD, Pow DV, Tanaka K, Watson GS, Cook DG (2010) Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 69, 667-676.
50. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. Glia 32, 1-14.
51. Kanai Y, Smith CP, Hediger MA (1993) A new family of neurotransmitter transporters: The high-affinity glutamate transporters. FASEB J 7, 1450-1459.
52. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65, 1-105.
53. Furness DN, Dehnes Y, Akhtar AQ, Rossi DJ, Hamann M, Grutle NJ, Gundersen V, Holmseth S, Lehre KP, Ullensvang K,Wojewodzic M, Zhou Y, Attwell D, Danbolt NC (2008) A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: New insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2). Neuroscience 157, 80-94.
54. Lehre KP, Danbolt NC (1998) The number of glutamate transporter subtype molecules at glutamatergic synapses: Chemical and stereological quantification in young adult rat brain. J Neurosci 18, 8751-8757.
55. Herman MA, Jahr CE (2007) Extracellular glutamate concentration in hippocampal slice. J Neurosci 27, 9736-9741.
56. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H 3rd, Kraner SD, Norris CM (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 29, 12957-12969.
57. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11, 97-116.
58. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40, 759-766.
59. Li S, Mallory M, Alford M,Tanaka S, MasliahE(1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56, 901-911.
60. Sasaki K, Shimura H, Itaya M, Tanaka R, Mori H, Mizuno Y, Kosik KS, Tanaka S, Hattori N (2009) Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains. FEBS Lett 583, 2194-2200.
61. Beckstrom H, Julsrud L, Haugeto O, Dewar D, Graham DI, Lehre KP, Storm-Mathisen J, Danbolt NC (1999) Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J Neurosci Res 55, 218-229.
62. Maragakis NJ, Dykes-HobergM, Rothstein JD (2004) Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 55, 469-477.
63. Guo Z, Ersoz A, Butterfield DA, Mattson MP (2000) Beneficial effects of dietary restriction on cerebral cortical synaptic terminals: Preservation of glucose and glutamate transport and mitochondrial function after exposure to amyloid betapeptide, iron, and 3-nitropropionic acid. J Neurochem 75, 314-320.
64. Guo ZH, Mattson MP (2000) Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex 10, 50-57.
65. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A,Waeg G, Mattson MP (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69, 273-284.
66. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta1-42. J Neurochem 78, 413-416.
67. Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin L, Bummer P, Wang Y, Pedigo NW Jr, Butterfield DA(1995) beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: Implications for Alzheimer's disease. Neuroreport 6, 1875-1879.
68. Harris ME, Wang Y, Pedigo NW Jr, Hensley K, Butterfield DA, Carney JM(1996) Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 67, 277-286.
69. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
70. Begni B, Brighina L, Sirtori E, Fumagalli L, Andreoni S, Beretta S, Oster T, Malaplate-Armand C, Isella V, Appollonio I, Ferrarese C (2004) Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease. Free Radic Biol Med 37, 892-901.